Hmn-448 !link!

. However, the term "HMN" is frequently used in medical literature as an abbreviation for Hereditary Motor Neuropathy National Institutes of Health (.gov)

The clinical development of HMN-448 is currently underway, with several trials investigating its safety and efficacy in patients with various types of cancer. These trials aim to evaluate the optimal dosing regimen, assess the compound's pharmacokinetics and pharmacodynamics, and explore its potential in combination with other therapies. HMN-448